Skip to main content
Scott Rodig, MD, Pathology, Boston, MA

ScottJRodigMD

Pathology Boston, MA

Hematopathology, Anatomic Pathology, Clinical Pathology

Associate Professor, Pathology-Brigham & Women's Hospital, Harvard Medical School

Are you Dr. Rodig?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 39 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    75 Francis St
    Brigham & Women's Hospital, Dept. Of Pathology, Amory 3
    Boston, MA 02115
    Phone+1 617-732-7510

Summary

  • Dr. Scott Rodig, MD is a board certified pathologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Brigham and Women's Hospital and is an Associate Professor at Harvard Medical School.

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1998 - 2002
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 1998

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2002 - 2025
  • American Board of Pathology Anatomic Pathology
  • American Board of Pathology Hematology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • New Research Shows Which Ovarian Cancer Patients Won't Benefit from Immune-PARP Combo
    New Research Shows Which Ovarian Cancer Patients Won't Benefit from Immune-PARP ComboMarch 19th, 2020
  • Research Update: Biomarkers as Predictors of Immunotherapy Response in Melanoma
    Research Update: Biomarkers as Predictors of Immunotherapy Response in MelanomaSeptember 13th, 2018
  • Study Finds Melanoma Biomarkers Predicting Checkpoint Blocker Response
    Study Finds Melanoma Biomarkers Predicting Checkpoint Blocker ResponseJuly 18th, 2018
  • Join now to see all